EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial)

Pichanon Mingchay, Kamon Kawkitinarong iD, Pattama Torvorapanit iD, Pirapon June Ohata, Gompol Suwanpimolkul iD

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf580 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Pichanon Mingchay und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Tuberculosis, Pulmonary, Sputum, Bronchodilator Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Ratchadapisek Research Funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Delayed pulmonary tuberculosis (PTB) diagnosis, especially with limited bronchoscopy resources, worsens outcomes and increases transmission risks. Sputum induction offers a noninvasive and effective alternative. We investigated whether adding nebulized bronchodilators improves sputum induction effectiveness for presumed PTB.

Methods

In a randomized controlled trial at King Chulalongkorn Memorial Hospital, Thailand, 204 adults with presumed PTB and negative Xpert MTB/RIF Ultra results or inadequate sputum production were enrolled between July and October 2024. Participants were randomly assigned to conventional sputum induction (3% hypertonic saline alone; n = 101) or bronchodilator-enhanced induction (nebulized bronchodilator plus 3% hypertonic saline; n = 103). The primary outcome was TB diagnosis by Xpert MTB/RIF assay.

Results

Tuberculosis detection rates by Xpert MTB/RIF were significantly higher in the bronchodilator-enhanced group (30.1%; number needed to diagnose [NND] = 4) versus the conventional group (17.8%; NND = 6), with a 12.3% difference (relative risk [RR], 1.68; 95% confidence interval [CI] 1.01–2.80). The group receiving bronchodilator co-administration showed a trend toward higher mycobacterial culture positivity (RR 1.49; 95% CI .93–2.41) and a lower need for bronchoscopy (RR 0.41; 95% CI .15–1.12). They also experienced fewer adverse events and required fewer induction attempts, significantly assisting us to be able to provide early treatment to the patients (median 4.5 vs 14 days; P < .01). Subgroup analysis revealed a significant benefit among outpatients (RR 1.86; 95% CI 1.00–3.48).

Conclusions

Bronchodilator-enhanced sputum induction demonstrated superiority over conventional induction, with higher diagnostic yield, fewer adverse events, fewer invasive procedures, and significantly earlier TB treatment initiation, supporting its potential as a new standard for TB diagnosis. Clinical Trials Registration Thai Clinical Trials Registry (TCTR20240709001), registered on 9 July 2024.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, PulmonarySputumBronchodilator AgentsHumansMaleFemaleThailandMiddle AgedAdultAdministration, InhalationMycobacterium tuberculosisAgedNebulizers and VaporizersSoutheast Asian People

Stichwörter der Autor:innen

bronchodilator-enhanced sputum inductioncombined bronchodilator and hypertonic saline sputum inductionpulmonary tuberculosissputum induction

Substanzen

Bronchodilator Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Division of Pulmonary Medicine and Pulmonary Critical Care, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Research Centre, Bangkok, Thailand.
  • Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

ORCID-Profile: Kamon Kawkitinarong, Pattama Torvorapanit, Gompol Suwanpimolkul

Förderung

  • Ratchadapisek Research Funds

Zitieren

APA

Mingchay, P., Kawkitinarong, K., Torvorapanit, P., Ohata, P. J., & Suwanpimolkul, G. (2026). Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf580

Vancouver

Mingchay P, Kawkitinarong K, Torvorapanit P, Ohata PJ, Suwanpimolkul G. Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial). Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf580

BibTeX
@article{Mingchay2026,
  author = {Mingchay, Pichanon and Kawkitinarong, Kamon and Torvorapanit, Pattama and Ohata, Pirapon June and Suwanpimolkul, Gompol},
  title = {Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial)},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf580}
}
Kostenlos starten →